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Navajo Neurohepatopathy Is Caused by a Mutation
in the MPV17 Gene
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Navajo neurohepatopathy (NNH) is an autosomal recessive disease that is prevalent among Navajo children in the
southwestern United States. The major clinical features are hepatopathy, peripheral neuropathy, corneal anesthesia and
scarring, acral mutilation, cerebral leukoencephalopathy, failure to thrive, and recurrent metabolic acidosis with inter-
current infections. Infantile, childhood, and classic forms of NNH have been described. Mitochondrial DNA (mtDNA)
depletion was detected in the livers of two patients, suggesting a primary defect in mtDNA maintenance. Homozygosity
mapping of two families with NNH suggested linkage to chromosome 2p24. This locus includes the MPV17 gene, which,
when mutated, causes a hepatocerebral form of mtDNA depletion. Sequencing of the MPV17 gene in six patients with
NNH from ﬁve families revealed the homozygous R50Q mutation described elsewhere. Identiﬁcation of a single missense
mutation in patients with NNH conﬁrms that the disease is probably due to a founder effect and extends the phenotypic
spectrum associated with MPV17 mutations.
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Navajo neurohepatopathy (NNH [MIM 256810]) is an au-
tosomal recessive multisystem disorder prevalent in the
Navajo population of the southwestern United States. The
estimated incidence of the disease in the western Navajo
Reservation is 1 in 1,600 live births.1 Patients with NNH
present with liver disease, severe sensory and motor neu-
ropathy, corneal anesthesia and scarring, cerebral leu-
koencephalopathy, failure to thrive, and recurrent meta-
bolic acidosis with intercurrent illness.1–3 Three pheno-
types have been culled on the basis of age at onset and
clinical course. The infantile (i.e., onset before age 6 mo)
and childhood (i.e., onset between age 1 and 5 years)
forms of NNH are dominated by severe hepatopathy and
early death from liver failure. The classic form of NNH is
characterized by moderate liver dysfunction and progres-
sive neuropathy. Peripheral and CNS demyelination is
seen in all three forms. Clinical heterogeneity is illustrated
by the occurrence of the three different NNH forms in the
same family.1 To date, the genetic cause of NNH has re-
mained unknown.
The similar clinical, pathological, and biochemical fea-
tures seen in patients with NNH and in patients with
mtDNA depletion syndrome (MDS) suggested that abnor-
mal regulation of mtDNA copy number may be the pri-
mary defect in NNH.1,3 This concept was conﬁrmed by the
documentation of mtDNA depletion in liver biopsies from
two patients with NNH.3 This ﬁnding, in turn, prompted
us to sequence genes associated with MDS in these two
patients with NNH, including the genes encoding mito-
chondrial deoxyguanosine kinase (DGUOK [MIM
601465]),4 mitochondrial thymidine kinase (TK2 [MIM
188250]),5 succinate-CoA ligase ADP-forming b subunit
(SUCLA2 [MIM 603921]),6 and polymerase g (POLG [MIM
174763]),7 but we found no pathogenic mutations. The
sequencing of another candidate gene that encodes mi-
tochondrial transcription factor A (TFAM [MIM 600438])
also failed to reveal any potential mutations.
On the other hand, both historical anddemographicdata
from the Navajo population of the western Navajo Reser-
vation strongly suggested a founder effect as the origin of
NNH. In this situation, homozygosity mapping is a pow-
erful tool for the identiﬁcation of the disease-causing gene.
We therefore studied two extended Navajo kindreds in
which the disease segregated as an autosomal recessive trait
(ﬁg. 1). Three additional nuclear families with NNH were
enrolled at a later stage of our study (families 3–5) (ﬁg. 1).
Diagnostic criteria for NNH were reported by Holve et al.1
Family 1 has been described elsewhere1,8: patients V1,
V3, and V8 had the infantile, classic, and childhood, re-
spectively, forms of NNH, and patients V11 and V12—two
affected brothers of V8—also had classic NNH.1 During
the ﬁrst year of life, patient 1 (V11) had recurrent hypo-
glycemia and metabolic acidosis during febrile illnesses.
He had poor growth and delayed development; his height
and weight were !5th percentile, and he began walking
at age 2 years. In school, he had academic difﬁculties. At
age 10 years, he underwent medical evaluation for pro-
gressive muscle weakness. His gait was wide-based, and he
was unable to run or to hold heavy objects with his hands.
Examination revealed greater distal than proximal limb
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Figure 1. Families 1–5 with NNH. Family 1 was described by Singleton et al.8 and by Holve et al.1 The probands in families 4 (II-1)
and 5 (II-1) were reported as patients 1 and 2, respectively, by Vu et al.3 The nucleotide 149GrA transition in the MPV17 gene is
denoted by a plus sign (), and the normal sequence is denoted by a minus sign ().
weakness, stocking-glove sensory loss, and areﬂexia; nerve
conduction studies conﬁrmed the presence of a peripheral
neuropathy. Muscle biopsy revealed neurogenic atrophy.
He did not have corneal ulcerations or scarring. He had
no evidence of hepatomegaly or liver dysfunction, but his
serum g-glutamyltransferase (GGT) was mildly elevated.
By age 12 years, he had lost the ability to walk and to
swallow, which required him to be placed in a chronic
care facility, where he was fed through a gastrostomy tube.
He developed hepatic cirrhosis and died of liver failure at
age 16 years.
As an infant girl, patient 2 (V3) (reported as patient 12
by Holve et al.1) had recurrent hypoglycemia and meta-
bolic acidosis with febrile illnesses. At age 6 mo, it was
noted that she had poor growth and delayed motor de-
velopment. At age 2 years, when she ﬁrst walked, she had
distal limbmuscle weakness, wasting, and areﬂexia. Nerve
conduction studies revealed diffusely slow velocities. Se-
rum transaminases and GGT were two to three times the
upper limits of normal, and total and direct bilirubinwere
mildly elevated. Her weakness worsened and, by age 4
years, she could move only by pulling herself across the
ground. Because of distal sensory loss, she had acral mu-
tilation complicated by recurrent skin infections. She also
had corneal anesthesia and developed corneal ulcers. Her
IQ was 72. Brain magnetic resonance imaging (MRI) re-
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vealed diffuse leukoencephalopathy, which was particu-
larly prominent in the cerebellum. By age 16 years, she
needed a wheelchair because of her neuropathy and had
poor vision due to corneal scarring. At age 20 years, she
had hematemesis, and evaluation revealed esophageal var-
ices and cirrhosis. She died of liver failure.
Patient 3 (III-6 in family 2) was reported as patient 17
by Holve et al.1 This boy had classic NNH. He had an older
sister (reported as patient 1 by Holve et al.1) who died of
liver failure at age 1 year and who was presumed to have
NNH. In infancy, he had gross motor delay and poor
growth; he began walking at age 2 years, and his height
and weight were !5th percentile. At age 3 years, he de-
veloped corneal ulcerations, and medical evaluation re-
vealed signs of peripheral neuropathy, including loss of
corneal sensation, stocking-glove sensory loss, distal limb
weakness, and areﬂexia. Nerve conduction studies re-
vealed marked slowing, and a sural nerve biopsy showed
severe loss of myelinated ﬁbers. Blood tests revealed ele-
vated transaminases and GGT but normal bilirubin. At age
4 years, he contracted varicella, which was complicated
by liver failure, acute respiratory distress syndrome, met-
abolic acidosis, and renal dysfunction, but he responded
to intensive care. Subsequently, he had persistently ele-
vated transaminases—two to three times the upper limit
of normal—and mild elevations of total and direct bili-
rubin, and his neuropathy progressively worsened. By age
10 years, he was unable to walk or to feed or dress himself.
Acral mutilation due to sensory neuropathy caused re-
current infections. He was fed through a gastrostomy tube.
Brain MRI revealed leukoencephalopathy. At age 14 years,
he had hematemesis due to esophageal varices and cir-
rhosis. One year later, he died of hepatic failure.
Patient 4 (individual II-1 in family 3) was reported as
patient 4 by Holve et al.1 This girl had infantile NNH and
a second cousin (reported as patient 2 by Holve et al.1 and
patient 5 in this report) who received the diagnosis of
NNH. At age 6 mo, this infant girl presented with failure
to thrive, jaundice, and hepatomegaly. Laboratory studies
revealed elevated transaminases, GGT, and total and direct
bilirubin. Prothrobin time was prolonged. Liver biopsy
showed cholestasis, steatosis, and ﬁbrosis. One month
later, she underwent a successful liver transplant. Despite
adequate hepatic function, she had recurrent metabolic
acidosis and failed to gain weight. Neurological exami-
nation revealed hypotonia, distal limb weakness, and
gross and ﬁne motor delay. At age 3 years, she was unable
to stand without support. She had signs of peripheral neu-
ropathy; pain sensation was absent in her hands and feet,
corneal sensation was decreased, distal limb muscles were
weak and wasted, and tendon reﬂexes were absent. Nerve
conduction studies revealed slow conductions. Results of
a brain MRI were normal. At age 12 years, the patient’s
donor liver is functioning well, but her height and weight
remain !5th percentile, and her peripheral neuropathy
continues to worsen.
Patient 5 (II-1 in family 4) had infantile NNH and was
reported as patient 1 by Vu et al.3 She had a second cousin
(patient 4 in this report) with infantile NNH. The patient
presented at age 1 mo with poor weight gain, and it was
noted that she had elevated levels of transaminases and
total and direct bilirubin. At age 4 mo, she was evaluated
for failure to thrive and was found to have hepatomegaly.
A liver biopsy revealed acute hepatocellular necrosis, cir-
rhosis, and micro- and macrovesicular steatosis. At age 15
mo, she had marked abdominal distention and ascites,
muscle wasting, hypotonia, and hyporeﬂexia. Brain MRI
revealed diffuse leukoencephalopathy. One month later,
she underwent liver transplantation. Her transplanted
liver functioned adequately, but she continued to have
failure to thrive and recurrent metabolic acidosis. A feed-
ing gastrostomy tube was placed. At age 2 years, she de-
veloped aspiration pneumonia and gram-negative sepsis
and died. Subsequent histochemical analysis of liver tissue
obtained at transplantation showed COX deﬁciency and
normal-to-increased succinate dehydrogenase activity in
most of the hepatocytes.3 Biochemical studies of liver dem-
onstrated decreased activities of respiratory-chain enzyme
complexes I, III, and IV (containing mtDNA-encoded sub-
units) and markedly increased citrate synthase activity.3
Southern blot of liver mtDNA revealed 89% depletion.3
Patient 6 (II-1 in family 5) is a 21-year-old woman with
classic NNH and was reported as patient 2 by Vu et al.3 At
age 4 mo, she presented with seizures associated with hy-
poglycemia. Two months later, evaluation for failure to
thrive revealed mildly elevated transaminases. Liver bi-
opsies at age 20 mo showed micronodular cirrhosis, mild
steatosis, and intracellular glycogen accumulation. At age
11 years, she developed hepatocellular carcinoma and un-
derwent liver transplantation. Although her transplanted
liver functioned well, she developed a peripheral neurop-
athy. Nerve conduction studies showed slow velocities,
and brain MRI showed white-matter lesions. Limited stud-
ies performed on a small sample of the transplanted liver
revealed 82% depletion of mtDNA and, by biochemical
analyses, decreased COX but normal citrate synthase ac-
tivity.3 She had an affected older brother who also had
failure to thrive, hypoglycemia, and chronic liver failure
and who died at age 5 years from bleeding esophageal
varices.
After written informed consent under an institutional
review board–approved protocol, peripheral bloodwas ob-
tained from all patients and unaffected individuals stud-
ied. Blood DNA from 2 affected individuals (patients V3
from family 1 and III-6 from family 2) and from 15 un-
affected individuals was used for linkage analysis, and ge-
nomic DNA extracted from a liver biopsy sample previ-
ously obtained from patient V8 in family 1 was also used
in our study. All patients met described diagnostic criteria
for NNH.1 A genomewide scan was performed using a set
of 400 polymorphic DNAmicrosatellitemarkers at average
distances of 10 cM (ABI Prism Linkage Mapping Set MD-
10 [Applied Biosystems]). The PCR products were run on
an ABI Prism 310 Genetic analyzer. Genotypes were iden-
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Table 1. Two-Point LOD Scores for 10 Microsatellite
Markers Identiﬁed in a Genomewide Screen of 400 Markers
in Families 1 and 2 with NNH
Marker Chromosome
va
.0 .01 .05 .1 .2 .3 .4
D2S2211 2p25.1 1.32 1.27 1.07 .85 .49 .23 .07
D2S305 2p24.1 .98 .95 .84 .69 .42 .21 .06
D2S335 2q33.3 1.04 1.01 .86 .68 .39 .18 .06
D3S1263 3p25.3 1.21 1.18 1.06 .92 .62 .36 .15
D4S1572 4q24 .98 .95 .85 .72 .47 .24 .07
D5S406 5p15.32 1.42 1.38 1.20 .97 .55 .25 .08
D7S510 7p14.1 1.13 1.08 .92 .73 .42 .20 .06
D8S272 8q24.23 1.11 1.07 .90 .69 .37 .17 .07
D9S1826 9q34.3 1.20 1.16 1.02 .85 .54 .28 .10
D10S189 10p14 1.09 1.06 .93 .77 .49 .26 .09
a Two-point LOD ∼1.0 at for all 10 markers.vp 0
tiﬁed using Genescan and Genotyper software (Applied
Biosystems). Parametric two-point linkage analyses were
performed with the MLINK option of the computer pack-
age Linkage, version 5.1, with the assumption of auto-
somal recessive inheritance with 90% penetrance and a
mutation frequency of 1 in 100,000. Allele frequencies
were estimated with the haplotypes of all familymembers
included in the study. Recombination frequencies were
assumed to be equal in males and females.
The genotype analysis revealed that only one homo-
zygous haplotype, with microsatellite marker D2S305 at
chromosome 2p24.1, was shared by all affected individ-
uals and was either absent or heterozygous in unaffected
family members (data not shown). Interestingly, this mar-
ker was 1 of only 10 microsatellite markers that gave a
pairwise LOD score 1 (table 1). Further analysis using ad-
ditional polymorphic DNA markers ﬂanking lociD3S1263,
D5S406, D7S510, and D9S1826 excluded linkage to these
loci. On the basis of our microsatellite marker studies, we
also excluded mutations in two candidate genes—nuclear
respiratory factor-1 (NRF-1 [MIM 600879]) and mitochon-
drial endonuclease G (ENDOG [MIM 600440])—that are in-
volved in the maintenance of mtDNA copy number.
We then considered other candidate genes around chro-
mosomal locus D2S305, a region that contains several
genes involved in mitochondrial functions identiﬁed
through integrative genomics.9 One of them was MPV17
(MIM 137960), which has been recently associated with
a new hepatocerebral form of MDS.10 The close proximity
of this gene to our chromosomal locus—and the striking
similarities between the phenotype of the described pa-
tients with MPV17 mutations and the clinical picture of
infantile NNH—prompted us to perform direct mutation
analysis of this gene in our patients. Sequencing revealed
a homozygous R50Qmutation in our patients 1–6. Further
genetic analysis of all available unaffected individuals con-
ﬁrmed segregation of themutationwith the disease. Taken
together, the results of linkage analysis and the detection
of the same pathogenic R50Q mutation in patients pre-
senting with the three different forms of the disease show
that MPV17 is the causative gene for NNH. Analysis of
additional patients from different families with NNH is
needed to explore possible genetic heterogeneity in NNH.
Mpv17 gene insufﬁciency was produced in mice by a
retroviral insert in the genome that decreases its expres-
sion.11 Initially, Mpv17/ mice developed glomeroscle-
rosis. Previous studies suggested a peroxisomal localiza-
tion of the encoded protein.12 Subsequently, two homo-
zygous mutations in MPV17—R50Q in exon 2 and N166K
in exon 7—were identiﬁed in four patients withMDS from
two families, one of Italian and the other of Moroccan
origin.10 A third patient from a Canadian family was com-
pound heterozygous for R50Q in exon 2 and a 25-bp de-
letion in exon 7. Functional analysis of the mutations
performed in HeLa cells revealed that MPV17 is involved
in mtDNAmaintenance and in the regulation of oxidative
phosphorylation.10 Further studies described in the same
report10 indicated that the encoded protein is localized in
the inner mitochondrial membrane and that Mpv17/
mice had depletion of mtDNA in liver, similar to the hu-
man disease.
NNH is a well-deﬁned clinical entity. The overlapping
clinical features of the three forms seem to form a spec-
trum with an age-related transition from the devastating
infantile to the predominantly classic to the more benign
and slowly progressive neuropathic forms.1,8 It is unclear
why some patients succumb to hepatic failure in infancy.
With successful liver transplantations, patients with in-
fantile NNH (e.g., patients 4 and 5 in this report) develop
progressive peripheral neuropathy and CNS leukoence-
phalopathy similar to the patients with classic NNH. Be-
cause of the inevitable progression of neurological dys-
functions, liver transplantation has very limited value in
treatment of this disease. Neuropathy, a salient diagnostic
feature of NNH, is not common in other forms of infantile
MDS. Only patients with the benign, later-onset myo-
pathic form of MDS due to TK2 mutation and patients
with Alpers syndrome (MIM 203700) and POLGmutations
show subclinical neuropathy.
The phenotype of the six patients with MDS described
by Spinazzola et al.10 resembles one end of the NNH clin-
ical spectrum that is dominated by lethal early-onset he-
patopathy. Two of four affected infants in the Italian fam-
ily who had the same homozygous R50Q mutation as our
patients with NNH died before age 9 mo. Similar courses
were seen in patients 2-4 and 3-1 in the same report.10
Notably, the two surviving patients harboring a homo-
zygous R50Q mutation developed multiple brain lesions
and had delayed growth, both typical symptoms of
NNH.13,14 On the other hand, patient 4-1 developed pro-
gressive spinocerebellar ataxia, myoclonus of hands and
feet, mental retardation, and severe neurogenic kypho-
scoliosis, which are not among the clinical features of
NNH. Interestingly, the prolonged survival of this patient
to age 9 years, which was achieved by dietary control for
hypoglycemia, may have therapeutic implications for pa-
tients with the infantile and childhood forms of NNH.
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This phenotypic variability suggests that additional neu-
rohepatocerebral forms of MDS may be caused by muta-
tions in MPV17 in non-Navajo patients. Alternatively, the
prominent peripheral nervous system involvement in
NNH may indicate that additional unlinked modiﬁer
genes or epigenetic factors play a role in the determination
of the phenotype.
Liver samples from two patients with NNH have been
assessed for mtDNA depletion and respiratory-chain de-
fects. Both showed marked depletion (89% and 82% re-
ductions relative to controls) and corresponding reduced
activities of respiratory-chain complexes withmtDNA-en-
coded subunits. Because liver from one patient with in-
fantile NNH and from another with the classic form have
been the only ones studied, it is not possible to correlate
the severity of the mitochondrial defects with the NNH
subtypes. It is noteworthy that the mtDNA depletion in
liver of patients with NNH is similar to that observed in
liver of patients with Alpers syndrome (60%–97%mtDNA
depletion) due to POLG mutations,15–17 with hepatocere-
bral disease due to DGUOK mutations (61%–98% mtDNA
depletion),4,18 and with hepatic disease due toMPV17mu-
tations (170% mtDNA depletion).10
In conclusion, we identiﬁed, by homozygosity map-
ping, the genetic defect causing NNH, showing that a sin-
gle mutation in exon 2 of MVP17 accounts for the differ-
ent forms of the disease. The identiﬁcation of MPV17 as
the disease-causing gene will provide a deﬁnitive pre- and
postnatal diagnosis of NNH and will shed light on the
pathogenic mechanism of the disorder.
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